Regulatory News:
Vetoquinol (Paris:VETO), a leading global animal health company, has acquired a majority interest in Farmvet Systems Ltd. A thriving start-up based in Northern Ireland, Farmvet Systems digital know-how enables the strengthening of the role of the veterinary practitioner on cattle farms.
Interpreting the information available in livestock breeding centers has become a strategic activity for veterinarians. Each farm generates a constantly growing volume of data derived from different sources: biological analysis findings, management systems, government documentation, epidemiological information, milking statistics, etc. Thanks to the applications developed by Farmvet Systems, all of this data is collated on a single dashboard, allowing vets and breeders to share information and transform it into a decision making tool on the farm. Vetoquinol thus reinforces its position as a reference partner for vets and cattle breeders.
VetImpress, the main application developed by Farmvet Systems Ltd, is sold today in the United Kingdom and Ireland; Vetoquinol will make it available to vets around the world through is international sales network.
This platform is available to anyone operating in the management of the farm willing to enrich it and use it towards improving the animals' health and welfare. Vetoquinol hereby confirms it commitment to the 'one world one health' initiative.
The integration of Farmvet Systems applications into Vetoquinol's solutions is fully part of the Laboratory long term vision; to create an ecosystem where digital technologies, diagnostic tools and drugs compliment one another with a view to optimizing the vet's action as well as the effective management of the animal health and welfare.
Click on the link below to hear a 2-minute interview with Vetoquinol CEO Matthieu Frechin: https://www.youtube.com/embed/c_l_QsL8GZ4?autoplay=1
Next update: Q3 2018 sales October 18, 2018 after market close
About Vetoquinol
Vetoquinol is a leading global player in the animal health sector serving both the livestock (cattle and pigs) and pet (dogs and cats) markets.
As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia-Pacific region.
Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vetoquinol employed 2,141 people as of June 30, 2018.
Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).
For further information, go to: www.vetoquinol.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180906005689/en/
Contacts:
VETOQUINOL
Investor Relations
Marie-Josée Aubry-Rota, Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com
or
KEIMA COMMUNICATION
Investor and Media Relations
Emmanuel Dovergne, Tel.: +33 (0)1 56 43 44 63
emmanuel.dovergne@keima.fr